Skip 
Navigation Link

1215 South Walnut Ave.
Demopolis, AL 36732 map map 

Access to Care: 334.289.2410

Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Blood Donations Needed: Red CrossKeep Unused Meds Out of the Hands of AddictsFew U.S. Universities Are Smoke-FreeNeed Emergency Air Lift to Hospital? It Could Cost You $40,000California Took on Anti-Vaxxers, and WonAnti-Vaccine Movement a 'Man-Made' Health Crisis, Scientists WarnAHA News: Even the Threat of Homelessness May Bring Higher Stroke RiskFDA Warns Two Kratom Marketers About False ClaimsExperts Want Doctors to Add Vaping to Youth Prevention PitchMany Health Care Workers With Flu, Colds Still Go to Work: StudyGlobal Efforts to Cut Smoking Show Mixed ResultsOne Simple Food Substitution Might Help Save the PlanetAHA News: 3 Simple Steps Could Save 94 Million Lives WorldwideRace Affects Life Expectancy in Major U.S. CitiesDrugstores Often Don't Have Opioid Antidote in Stock, Philly Study ShowsAntibiotics Pollute Rivers Worldwide: StudyAHA News: For LGBTQ Patients, Discrimination Can Become Barrier to Medical CareImmigrants Make Up 1 in 4 U.S. Health Care WorkersFDA Takes Hard Look at CBDPatients Who Read Doctors' Notes More Likely to Take Their MedsU.S. Measles Cases for 2019 Already Exceed All Annual Totals Since 1992: CDCBreathe Easier, New York City: Clean-Air Taxi Rules Are WorkingDoctor Burnout Costly for Patients, Health Care SystemBlood Banks Could Help Screen for Hereditary High CholesterolRed Cross Needs Type O Blood to Ease ShortageLess Pain, More Car Crashes: Legalized Marijuana a Mixed BagPolitical Controversies Could Fuel Bullying of LGBT Youth: StudyCBD -- It's Everywhere, But Does It Work?Brief EMS Training Saves Lives After Brain InjuryU.S. Improves Emergency Readiness, but Gaps PersistSlowing Climate Change Could Cut Health Costs, Save MoneyDispensing Opioid Antidote Without a Prescription Might Save LivesNot Just Opioids: Deaths Tied to Cocaine, Meth Are Soaring, TooMost Americans Hit Hard by Medical BillsYour Virtual Doctor Will 'See' You NowHigh Measles Rates Mean Kids, Adults Need Proper Vaccination: CDCMany Drivers Testing Positive for Marijuana, Even With Kids in CarMedicaid Could Save $2.6 Billion a Year With Dip in SmokingFDA Halts All Sales of Pelvic Mesh Products Tied to Injuries in WomenAnother Cost of the Opioid Epidemic: Billions of Dollars in Lost TaxesHealth Tip: Using an AEDNurse Practitioners Often Restricted From Prescribing Opioid TreatmentsForested Counties Have Lower Medicare Costs, Study FindsSimple CPR Doubles Survival OddsUninsured Get Short Shrift on Hospital StaysSpecial Bag Helps Patients Get Rid of Unused OpioidsHealth Tip: Responsibilities of Non-VaccinationDo Doctors Hounded by Malpractice Claims Just Shift Their Practice Elsewhere?Bans on Texting While Behind the Wheel Making Roads SaferColorado Sees Spike in ER Visits After Pot Made Legal
Questions and AnswersVideosLinksBook Reviews
Related Topics

Health Insurance
Healthcare

Drug Studies in Children Often Go Unfinished: Study

HealthDay News
by -- Robert Preidt
Updated: Nov 19th 2018

new article illustration

MONDAY, Nov. 19, 2018 (HealthDay News) -- Drug approvals for adults often require future studies in children, but many of these studies are never completed, a new analysis finds.

"More than 50 percent of all drugs approved by the FDA lack information on how to safely and effectively use the drug in children," said study author Dr. Florence Bourgeois, from the Pediatric Therapeutics and Regulatory Science Initiative at Boston Children's Hospital.

Her team examined 114 new drugs or new uses for drugs that were approved by the U.S. Food and Drug Administration between 2007 and 2014. In all, a total of 222 postmarketing studies in children were required for these approvals.

But only 34 percent of those studies had been completed by December 2017. Of those completed, only 45 percent had results reported in a journal.

At the time of FDA approval, only 16 percent of the drugs approved with postmarketing child studies had any information on child-related efficacy, safety or dosing on their labels. This rose to only 41 percent after an average follow-up of seven years.

"As a clinician, I was struck early on by how little evidence we often have to guide medication use in children. Although the FDA has an established process to ensure medicines are safe and effective in adults, this has historically been lacking for children," Bourgeois said in a hospital news release.

"Unfortunately, we are still seeing long delays between the approval of a drug and the availability of pediatric information. This perpetuates off-label drug use that may be unsafe or ineffective," she said.

Additional FDA oversight and use of enforcement tools are needed to ensure follow-up studies are completed, the researchers said.

The study was published Nov. 19 in the journal JAMA Pediatrics.

More information

The U.S. Food and Drug Administration has more on postmarketing clinical trials.